Matches in Wikidata for { <http://www.wikidata.org/entity/Q91572054> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q91572054 description "article scientifique publié en 2018" @default.
- Q91572054 description "artículu científicu espublizáu en setiembre de 2018" @default.
- Q91572054 description "scientific article published on 20 September 2018" @default.
- Q91572054 description "wetenschappelijk artikel" @default.
- Q91572054 description "наукова стаття, опублікована у вересні 2018" @default.
- Q91572054 name "Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years" @default.
- Q91572054 name "Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years" @default.
- Q91572054 type Item @default.
- Q91572054 label "Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years" @default.
- Q91572054 label "Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years" @default.
- Q91572054 prefLabel "Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years" @default.
- Q91572054 prefLabel "Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years" @default.
- Q91572054 P1433 Q91572054-36A546D2-ABD8-4B86-82CA-D7B4A010F2EA @default.
- Q91572054 P1476 Q91572054-11465721-4270-4EBD-9064-57D084635E1A @default.
- Q91572054 P2093 Q91572054-0E9A2011-8A0B-4405-9415-F66F67254E1E @default.
- Q91572054 P2093 Q91572054-524B1AFB-CEE4-424B-9861-D3D0542F5CCD @default.
- Q91572054 P2093 Q91572054-6D6A0D66-05D7-4AA8-9247-55E49D91C977 @default.
- Q91572054 P2093 Q91572054-7F84D6C7-8A98-4B80-887D-18FD3BAEF069 @default.
- Q91572054 P2093 Q91572054-861941B9-067C-40EC-B36E-03E85E8591A6 @default.
- Q91572054 P2093 Q91572054-93497FB9-4FFD-481C-B38E-312FE593607F @default.
- Q91572054 P2093 Q91572054-A6D3607B-F218-4C5C-9BF3-6A61DDC7371D @default.
- Q91572054 P2093 Q91572054-B01643D5-E67C-4EF1-AE98-61D4011D62E3 @default.
- Q91572054 P2093 Q91572054-C75E557B-17C0-47F6-99CD-12BDDEA97511 @default.
- Q91572054 P304 Q91572054-DBF4996B-DC2D-4829-AE34-CEEE23B73ACF @default.
- Q91572054 P31 Q91572054-ABE3F558-CD3C-490B-8C23-A21ED23FB20A @default.
- Q91572054 P356 Q91572054-49285524-6B3E-4BBB-9039-4CCB5BCF4448 @default.
- Q91572054 P433 Q91572054-082BC533-A061-4C39-B02C-37633917785B @default.
- Q91572054 P478 Q91572054-1094257E-66AD-48DE-9A0A-8FA17DF253D4 @default.
- Q91572054 P50 Q91572054-3A8BF137-28D6-4784-92DC-CA235A3EE4F8 @default.
- Q91572054 P50 Q91572054-5490900E-9D53-4CFB-B46C-6EAAB2E0607C @default.
- Q91572054 P50 Q91572054-A83D4D13-1529-482F-911E-955F34D50E1F @default.
- Q91572054 P50 Q91572054-CE65FE52-0316-4E26-AC18-F84F7423701B @default.
- Q91572054 P577 Q91572054-8F12A977-0BAB-4E66-878D-F416F999861F @default.
- Q91572054 P698 Q91572054-A4B02969-5361-4950-A893-7666CE8D364B @default.
- Q91572054 P921 Q91572054-D5A720A0-7B09-45B8-9420-E9E5B6664A29 @default.
- Q91572054 P356 10428194.2018.1509322 @default.
- Q91572054 P698 30234403 @default.
- Q91572054 P1433 Q6534493 @default.
- Q91572054 P1476 "Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years" @default.
- Q91572054 P2093 "Antonio Rueda" @default.
- Q91572054 P2093 "Cristina Quero Blanco" @default.
- Q91572054 P2093 "Francisco Garcia-Arroyo" @default.
- Q91572054 P2093 "Josep Gumá" @default.
- Q91572054 P2093 "José Ignacio Chacón" @default.
- Q91572054 P2093 "Juan Ramón Delgado" @default.
- Q91572054 P2093 "Luis de la Cruz" @default.
- Q91572054 P2093 "Marta Llanos" @default.
- Q91572054 P2093 "Ruth Álvarez" @default.
- Q91572054 P304 "856-859" @default.
- Q91572054 P31 Q13442814 @default.
- Q91572054 P356 "10.1080/10428194.2018.1509322" @default.
- Q91572054 P433 "3" @default.
- Q91572054 P478 "60" @default.
- Q91572054 P50 Q117228120 @default.
- Q91572054 P50 Q117228121 @default.
- Q91572054 P50 Q53051637 @default.
- Q91572054 P50 Q86563381 @default.
- Q91572054 P577 "2018-09-20T00:00:00Z" @default.
- Q91572054 P698 "30234403" @default.
- Q91572054 P921 Q123251 @default.